Relevance of serum biomarkers in the therapy of ventricular arrhythmias in cardiac sarcoidosis

• Conditions: D86; Sarcoidosis

• Registration Number: DRKS00027545
• Lead Sponsor: HELIOS Klinikum München WestKardiologie und Internistische Intensivmedizin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2021-12-31
• Study Start: 2022-01-06
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

biopsy-proven cardiac sarcoidosis with ventricular arrhythmias

Exclusion Criteria

age < 18 years

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determination of the relevance of the serum biomarkers sIL2-R and ACE in the treatment of ventricular arrhythmias in cardiac sarcoidosis

Secondary Outcome Measures

Name	Time	Method
Clinical follow-up of patients with ventricular arrhythmias in cardiac sarcoidosis